TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zelira Therapeutics ( (AU:ZLD) ) just unveiled an update.
Zelira Therapeutics has announced its upcoming Annual General Meeting, scheduled for November 19, 2025, which will be held both virtually and physically in Perth. Key agenda items include the adoption of the remuneration report, re-election of director Greg Blake, and approval of convertible notes for Dr. Oludare Odumosu and Dr. Donna Gentile O’Donnell. Additionally, the company seeks to renew its proportional takeover provisions in the constitution. These resolutions, if passed, could impact the company’s governance and financial strategies, potentially influencing shareholder value and market perception.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics Limited operates in the pharmaceutical industry, focusing on the development and commercialization of cannabinoid-based medicines. The company targets therapeutic areas such as pain management, sleep disorders, and anxiety, aiming to leverage the growing interest in medical cannabis products.
YTD Price Performance: -43.55%
Average Trading Volume: 4,380
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.16M
See more data about ZLD stock on TipRanks’ Stock Analysis page.